Characterization of a DNA Aptamer for Ovarian Cancer Clinical Tissue Recognition and in Vivo Imaging

Li, Fengjie; Wang, Qian; Zhang, Hui; Deng, Tanggang; Feng, Peifu; Hu, Bin; Jiang, Yanping; Cao, Lei

doi:10.1159/000495925

Cited by 21 publications

(11 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A number of aptamers have been designated for various diseases, eg, types of cancers. 21,22 Table 1 describes a list of the most common differences between an antibody and aptamer.…”

Section: Introductionmentioning

confidence: 99%

<p>Aptamer Hybrid Nanocomplexes as Targeting Components for Antibiotic/Gene Delivery Systems and Diagnostics: A Review</p>

Rabiee¹,

Ahmadi²,

Arab³

et al. 2020

IJN

View full text Add to dashboard Cite

With the passage of time and more advanced societies, there is a greater emergence and incidence of disease and necessity for improved treatments. In this respect, nowadays, aptamers, with their better efficiency at diagnosing and treating diseases than antibodies, are at the center of attention. Here, in this review, we first investigate aptamer function in various fields (such as the detection and remedy of pathogens, modification of nanoparticles, antibiotic delivery and gene delivery). Then, we present aptamer-conjugated nanocomplexes as the main and efficient factor in gene delivery. Finally, we focus on the targeted co-delivery of genes and drugs by nanocomplexes, as a new exciting approach for cancer treatment in the decades ahead to meet our growing societal needs.

show abstract

“…A number of aptamers have been designated for various diseases, eg, types of cancers. 21,22 Table 1 describes a list of the most common differences between an antibody and aptamer.…”

Section: Introductionmentioning

confidence: 99%

<p>Aptamer Hybrid Nanocomplexes as Targeting Components for Antibiotic/Gene Delivery Systems and Diagnostics: A Review</p>

Rabiee¹,

Ahmadi²,

Arab³

et al. 2020

IJN

View full text Add to dashboard Cite

show abstract

“…Ovarian cancer is one of the most lethal gynecologic tumors that are not easy to be detected at an early stage, which contributes to a high mortality rate. In a clinical study of ovarian cancer patients, the affinity of R13 aptamer with cancer cells was studied through flow cytometry analysis [ 47 ]. Additionally, the stability of R13 aptamer was also analyzed in an ovarian cancer patient’s blood serum.…”

Section: Aptamers In Cancer Diagnosismentioning

confidence: 99%

Current Perspectives on Aptamers as Diagnostic Tools and Therapeutic Agents

2020

View full text Add to dashboard Cite

Aptamers are synthetic single-stranded DNA or RNA sequences selected from combinatorial oligonucleotide libraries through the well-known in vitro selection and iteration process, SELEX. The last three decades have witnessed a sudden boom in aptamer research, owing to their unique characteristics, like high specificity and binding affinity, low immunogenicity and toxicity, and ease in synthesis with negligible batch-to-batch variation. Aptamers can specifically bind to the targets ranging from small molecules to complex structures, making them suitable for a myriad of diagnostic and therapeutic applications. In analytical scenarios, aptamers are used as molecular probes instead of antibodies. They have the potential in the detection of biomarkers, microorganisms, viral agents, environmental pollutants, or pathogens. For therapeutic purposes, aptamers can be further engineered with chemical stabilization and modification techniques, thus expanding their serum half-life and shelf life. A vast number of antagonistic aptamers or aptamer-based conjugates have been discovered so far through the in vitro selection procedure. However, the aptamers face several challenges for its successful clinical translation, and only particular aptamers have reached the marketplace so far. Aptamer research is still in a growing stage, and a deeper understanding of nucleic acid chemistry, target interaction, tissue distribution, and pharmacokinetics is required. In this review, we discussed aptamers in the current diagnostics and theranostics applications, while addressing the challenges associated with them. The report also sheds light on the implementation of aptamer conjugates for diagnostic purposes and, finally, the therapeutic aptamers under clinical investigation, challenges therein, and their future directions.

show abstract

“… Zhu et al (2017) labeled the screened aptamers Heraptamer 1 and Heraptamer 2 with isotope 18 F, followed by PET imaging in a mouse model of ovarian cancer induced by SKOV3 cells, which exhibited high signal-to-background ratios within a short time and prevented aptamer degradation by nucleases. Li et al (2018) injected Cy5-labeled R13 aptamer into nude mice and performed fluorescent imaging for tumor and organs half an hour later. A weak fluorescent signal was obtained in the first 1.5 h, which peaked at 3.5 h, and lasted for 9.5 h. Zhu et al (2017) and Li et al (2018) demonstrated the feasibility of using aptamers for in vivo imaging and suggested more approaches for ovarian cancer diagnosis.…”

Section: Applications Of Aptamers In Ovarian Cancer Diagnosismentioning

confidence: 99%

Applications of Aptamers in the Diagnosis and Treatment of Ovarian Cancer: Progress From 2016 to 2020

Ruan

2021

Front. Genet.

View full text Add to dashboard Cite

Nucleic acid aptamers are short single-stranded DNA or RNA oligonucleotides selected from a random single-stranded nucleic acid library using systematic evolution of ligands by exponential enrichment technology. To allow them to bind to molecular targets with the same specificity and precision as that of antibodies, aptamers are folded into secondary or tertiary structures. However, compared to antibodies, aptamers are not immunogenic and are easier to synthesize. Furthermore, they are chemically modified, which protects them from degradation by nucleases. Hence, due to their stability and favorable targeting ability, aptamers are promising for the diagnosis and treatment of diseases. Ovarian cancer has the worst prognosis among all gynecological diseases and is usually diagnosed at the medium and advanced stages due to its nonspecific symptoms. Relapse is common, even if patients receive a standard therapeutic regimen including surgery and chemotherapy; simultaneously, drug resistance and adverse effects are reported in a several patients. Therefore, the safer and more efficient diagnostic and treatment method for ovarian cancer is imperative. Scientists have been trying to utilize aptamer technology for the early diagnosis and accurate treatment of ovarian cancer and some progress has been made in this field. This review discusses the screening of nucleic acid aptamers by targeting ovarian cancer cells and the application of aptamers in the diagnosis and treatment of ovarian cancer.

show abstract

Characterization of a DNA Aptamer for Ovarian Cancer Clinical Tissue Recognition and in Vivo Imaging

Cited by 21 publications

References 32 publications

<p>Aptamer Hybrid Nanocomplexes as Targeting Components for Antibiotic/Gene Delivery Systems and Diagnostics: A Review</p>

<p>Aptamer Hybrid Nanocomplexes as Targeting Components for Antibiotic/Gene Delivery Systems and Diagnostics: A Review</p>

Current Perspectives on Aptamers as Diagnostic Tools and Therapeutic Agents

Applications of Aptamers in the Diagnosis and Treatment of Ovarian Cancer: Progress From 2016 to 2020

Contact Info

Product

Resources

About